Spots Global Cancer Trial Database for Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Official Title: Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas

Study ID: NCT00991211

Conditions

Non-Hodgkin Lymphomas

Follicular Lymphomas

Immunocytomas

Lymphocytic Lymphomas

Marginal Zone Lymphomas

Interventions

Bendamustine

Standard chemotherapy CHOP + Ritiximab

Study Description

Brief Summary: The study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus rituximab with regard to progression free survival (PFS).

Detailed Description: The 4 agent chemotherapy (CTX) CHOP (cyclophosphamide, doxorubicin, vincristine prednisone) in combination with the monoclonal anti-CD20 antibody rituximab (CHOP-R) represents a standard CTX for the treatment of lymphomas of high or low malignancy. The combination of bendamustine and rituximab (B-R) is also highly effective with a more advantageous toxicity profile. If B-R could be shown to be non inferior to CHOP-R, this could improve the quality of life of the patient and possibly also the prognosis.